Monoclonal antibodies (mAbs) have become the fastest growing class of therapeutics owing to their beneficial impacts in treating many life-threatening diseases. NMR methods have been recently introduced for quality control of therapeutic mAbs batches. However, the lack of methods to produce suitably labelled mAbs and Fabs, hampered the structural studies of mAbs at atomic resolution using high resolution NMR.
We have extended our methyl specific labelling strategies to 13CH3-labeling of proteins produced in vitro or in eukaryotic cells. This methods enable us to obtain the first assignment of a therapeutic Fab. We are currently applying these approaches to study dynamics of therapeutic mAbs and interaction with human target proteins.
Key Publications
“Enabling Site Specific NMR Investigations of Therapeutic Fab using a Cell-Free Based Isotopic Labeling Approach:Application to anti-LAMP1 Fab” Journal of Biomolecular NMR
